Sensus Healthcare, Inc.SRTS

Sensus Healthcare’s first-quarter 2026 filing reads like a medical device company that forgot to invoice the patient. The company reported revenue of $3.4 million, a net loss of $2.6 million, and $3.8 million of cash burned in operations, all while adding $2.4 million to its inventory pile, which now stands at $16.5 million. The numbers suggest the company’s growth story is still more aspiration than execution, and its $18.3 million cash balance is the kind of cushion that feels thinner with every quarterly filing.

What Sensus actually does is sell non-invasive radiation therapy devices-specifically its SRT-100, SRT-100 Vision, and Sensus V -designed to treat non-melanoma skin cancer without surgery. The company positions itself as a leader in cutaneous radiation oncology, but the balance sheet tells a different story: revenue is down from $27.5 million in the year-ago period, and the company’s reliance on MedIQ Healthcare Solutions for reimbursement support hints that the real work isn’t just treating patients but convincing insurers to foot the bill. The glossy product page features a sleek MPO device, yet the filing doesn’t disclose how many units were sold, shipped, or reimbursed in the quarter, leaving investors to guess whether the inventory build is a sign of pent-up demand or a storage headache.

The numbers are sourced directly from Sensus’s latest 10-Q for the period ending 31 March 2026. Revenue was $3.4 million, net loss was $2.6 million, operating loss was $4.4 million, cash used in operations was $3.8 million, and inventory increased by $2.4 million to $16.5 million. Cash and equivalents stood at $18.3 million, while total assets were $51.5 million against $6.0 million in liabilities. Diluted EPS was -$0.16 on 16.5 million weighted average shares. The company’s research and development spend was $1.6 million, and capital expenditure was a rounding error at $3,000. The filing does not break out the number of devices sold, installed, or reimbursed, nor does it provide segment-level detail beyond total revenue.

For a deeper look at the company’s technology and pipeline, Sensus’s official pages outline its three FDA-cleared SRT devices and its new High-Frequency Ultrasound for Image Guidance, while the clinical studies page highlights partnerships like MedIQ for reimbursement support. The company’s latest press releases trumpet financial results and new financing arrangements, but the filings themselves don’t quantify device utilisation or reimbursement success rates. If you’re trading this name, the key documents to watch are the 10-Q, 8-Ks on financing, and the Form SD for conflict minerals, all of which are available via the SEC’s EDGAR portal.

The absence of device-level sales data and reimbursement metrics means the source requires readers to infer performance from aggregate revenue, cash burn, and inventory trends. The filing’s silence on utilisation rates leaves a material gap: we know how much cash is going out, but not how much value is coming in. A future 10-Q or investor presentation that discloses installed base growth, reimbursement approvals, or average utilisation per device would materially reduce the opacity. Until then, the story remains a gap between the polished platform narrative and the balance sheet’s arithmetic.